The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A study of Boston Scientific’s Farapulse pulsed field ablation system met safety and efficacy objectives in people with persistent atrial fibrillation (AFib), an irregular heart rhythm that lasts more ...

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary system that ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...